NewEdge Advisors’s Pyxis Oncology PYXS Stock Holding History

NewEdge Advisors’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15K	Hold	10,250	–	–	﹤0.01%	3288
2025 Q4	$11.8K	Buy	10,250 +10,000	+4,000%	+$35.3K	﹤0.01%	3423
2025 Q3	$555	Hold	250	–	–	﹤0.01%	3942
2025 Q2	$275	Hold	250	–	–	﹤0.01%	3860
2025 Q1	$245	Hold	250	–	–	﹤0.01%	3784
2024 Q4	$390	Hold	250	–	–	﹤0.01%	3692
2024 Q3	$918	Hold	250	–	–	﹤0.01%	3527
2024 Q2	$828	Hold	250	–	–	﹤0.01%	3505
2024 Q1	$1.06K	Hold	250	–	–	﹤0.01%	3483
2023 Q4	$450	Sell	250 -1,542	-86%	-$2.64K	﹤0.01%	3542
2023 Q3	$3.57K	Hold	1,792	–	–	﹤0.01%	2901
2023 Q2	$4.59K	Buy	1,792 +1,542	+617%	+$4.89K	﹤0.01%	2847
2023 Q1	$1K	Buy	+250	New	+$499	﹤0.01%	3150

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NewEdge Advisors's PYXS Position: Q1 2026 in Review

NewEdge Advisors held its Pyxis Oncology (PYXS) position steady in Q1 2026 at 10,250 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #3288.

NewEdge Advisors first reported a position in PYXS in Q1 2023 and has held it in 13 quarters since. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

NewEdge Advisors held 10,250 shares of Pyxis Oncology worth $15K as of Q1 2026.
NewEdge Advisors left its Pyxis Oncology share count unchanged in Q1 2026.
Pyxis Oncology made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3288 holding.
NewEdge Advisors first reported a position in Pyxis Oncology in Q1 2023 and has held it in 13 quarters since.
78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.